$60,000 of INOVIO PHARMACEUTICALS lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"General issues related to rare disease and orphan drugs."
You can find more data on corporate lobbying on Quiver Quantitative.
INO Hedge Fund Activity
We have seen 44 institutional investors add shares of INO stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 884,817 shares (-9.5%) from their portfolio in Q2 2026, for an estimated $973,298
- D. E. SHAW & CO., INC. removed 880,155 shares (-39.4%) from their portfolio in Q2 2026, for an estimated $968,170
- TWO SIGMA INVESTMENTS, LP added 849,394 shares (+217.6%) to their portfolio in Q2 2026, for an estimated $934,333
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 804,958 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $885,453
- ADAR1 CAPITAL MANAGEMENT, LLC added 673,802 shares (+45.8%) to their portfolio in Q2 2026, for an estimated $741,182
- MILLENNIUM MANAGEMENT LLC removed 614,738 shares (-43.6%) from their portfolio in Q2 2026, for an estimated $676,211
- DIADEMA PARTNERS LP removed 533,682 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $587,050
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
